Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center
The aim of the present study was to retrospectively evaluate response to therapy in 73 patients affected by systemic sclerosis (SSc) who underwent long-term cyclic treatment with intravenous iloprost for peripheral vascular involvement (average duration of treatment 54.12±41.04 months). Seventy-thre...
Main Authors: | A. Di Vita, M. Mosca, A. D'Ascanio, P. Pepe, A. Della Rossa, S. Casigliani Rabl, S. Bombardieri |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2012-07-01
|
Series: | Reumatismo |
Subjects: | |
Online Access: | http://www.reumatismo.org/index.php/reuma/article/view/521 |
Similar Items
-
Iloprost Duration for Digital Ulcers in Systemic Sclerosis: French Retrospective Study at Two Centers and Literature Review
by: Céline Jamart, et al.
Published: (2022-07-01) -
Effect of cyclic intravenous Iloprost therapy in patients with Idiopathic Pulmonary Artery Hypertension
by: Majid MalekMohammad, et al.
Published: (2017-02-01) -
Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens
by: T. Schioppo, et al.
Published: (2019-07-01) -
Iloprost Attenuates Oxidative Stress-Dependent Activation of Collagen Synthesis Induced by Sera from Scleroderma Patients in Human Pulmonary Microvascular Endothelial Cells
by: Roberta Giordo, et al.
Published: (2021-08-01) -
Efficacy of inhaled iloprost in children with pulmonary hypertension after pediatric cardiac surgery: a case series
by: Ergin Arslanoğlu, et al.
Published: (2024-04-01)